PTGX NASDAQ
Protagonist Therapeutics, Inc.
1W: -3.4%
1M: -3.4%
3M: +23.3%
YTD: +17.0%
1Y: +118.9%
3Y: +301.6%
5Y: +234.8%
$99.19
-2.82 (-2.76%)
Weekly Expected Move ±6.0%
$90
$96
$102
$108
$114
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (47)
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
J&J's Pipeline Progress & New Drugs Promise Stronger Long-Term Growth
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
Protagonist GAAP EPS of $0.05 beats by $0.65, revenue of $56.37M
How to Play J&J Stock Post a Beat-and-Raise Performance in Q1
Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Moderate Buy” from Analysts
Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday
SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High – Should You Buy?
Arturo Md Molina Sells 15,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells $2,581,503.60 in Stock
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 24,000 Shares of Stock
Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?
Dinesh Ph Patel Sells 54,641 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026
J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
J&J Expands New Drug Portfolio With Icotyde's FDA Approval
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie
J&J’s new psoriasis pill to rival AbbVie’s Skyrizi: BNP Paribas
J&J wins FDA nod for plaque psoriasis pill developed with Protagonist
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of “Moderate Buy” by Brokerages
Atika Capital Management LLC Takes $5.51 Million Position in Protagonist Therapeutics, Inc. $PTGX
Protagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc.
HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX
Protagonist GAAP EPS of -$0.69 misses by $0.20, revenue of $7.44M
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 5,000 Shares
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 4,068 Shares
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 13,151 Shares of Stock
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares of Stock
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 19,315 Shares
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 24,890 Shares of Stock
Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Moderate Buy” from Analysts
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
Bosun Asset Management LLC Acquires New Position in Protagonist Therapeutics, Inc. $PTGX
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Commonwealth of Pennsylvania Public School Empls Retrmt SYS